

## Regulatory Announcement

RNS Number : 3432L  
Akers Biosciences, Inc.  
08 January 2009

8 January 2009-Correction

The following amended text replaces RNS Number:3247L issued at 12.00 today.

### **Akers Biosciences Inc.**

#### **Grant of Warrants**

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the grant of warrants over a total of 2,110,000 common shares of nil par value to the following Directors:

<i>Director</i>	<i>Exercise Price (p)</i>	<i>Number of warrants</i>	<i>Resultant holding of warrants</i>
Thomas A. Nicolette	12	500,000	4,050,000
Edward Mulhare	12	500,000	844,000
Raymond Akers	12	500,000	5,550,000
Daniel Seckinger	12	500,000	932,000
Charles Bunker	12	110,000	110,000

The warrants are exercisable immediately and have a 10 year term.

#### **Enquiries:**

Thomas A. Nicolette  
President and CEO  
Tel. +1 856 848 8698

Ben Simons  
M: Communications  
Tel. +44 (0)20 7153 1540

Alasdair Younie  
Arbuthnot Securities Limited  
Tel. +44 (0)20 7012 2000

**About Akers Biosciences**

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at [www.akersbiosciences.com](http://www.akersbiosciences.com).

This information is provided by RNS  
The company news service from the London Stock Exchange

END